Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2814 in Dominantly Inherited Alzheimer's Disease
NCT04971733Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2021
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of etalanetug in Alzheimer's disease (AD) (2 cohorts), sponsored by Eisai Co., Ltd. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs up to 120 weeks, Number of Participants With Markedly Abnormal Laboratory Values up to 120 weeks and 3 more. Started Jun 2021; status: completed.
02
Drugs
etalanetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04971733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971733.